Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2023 | The current landscape of treatment for frail myeloma patients at relapse & challenges in this space

Clark DuMontier • 22 Sep 2023
IMS 2023
Multiple Myeloma

In this video, Clark DuMontier, MD, MPH, VA Boston Healthcare System, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, discusses the challenges of optimizing treatment for elderly and frail patients with multiple myeloma at relapse. Dr DuMontier mentions the shift from prolongation of survival to preservation of quality of life (QoL) as patients age. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Clark DuMontier

Optimizing myeloma treatment for frail patients: dosing, scheduling and administration 4:42
Optimizing myeloma treatment for frail patients: dosing, scheduling and administration
Clark DuMontier • 22 Sep 2023
Treatment intensity in frail patients with newly diagnosed multiple myeloma: VRd vs Rd 9:11
Treatment intensity in frail patients with newly diagnosed multiple myeloma: VRd vs Rd
Clark DuMontier • 22 Sep 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals